Sarepta therapeutics posts non-gaap loss per share of $1.57

Sarepta therapeutics announces fourth quarter and full-year 2019 financial results and recent corporate developments.q4 non-gaap loss per share $1.57.q4 revenue $100.1 million versus refinitiv ibes estimate of $98.9 million.q4 earnings per share estimate $-1.86 -- refinitiv ibes data.had approximately $1.1 billion in cash, cash equivalents and investments as of december 31, 2019.sarepta therapeutics- qtrly net loss per share - basic and diluted $3.16.
SRPT Ratings Summary
SRPT Quant Ranking